Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Chitinase 1 (CHIT1) plays a role in the pathogenesis of pulmonary fibrosis by modulating canonical and noncanonical TGF-β signaling via interaction with TGFBRAP1 and FOXO3. These findings highlight the CHIT1/SMAD7 axis as a potential biomarker and therapeutic target of pulmonary fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361373 | PMC |
| http://dx.doi.org/10.26508/lsa.202402987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer.
Nat Cell Biol
September 2025
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Durotaxis, cell migration along stiffness gradients, is linked to embryonic development, tissue repair and disease. Despite solid in vitro evidence, its role in vivo remains largely speculative. Here we demonstrate that durotaxis actively drives disease progression in vivo in mouse models of lung fibrosis and metastatic pancreatic cancer.
View Article and Find Full Text PDF[Research status of diagnosis, treatment and prognosis of primary Sjögren's syndrome-associated interstitial lung disease].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, China-Japan
Interstitial lung disease (ILD) is a group of heterogeneous non-tumor and non-infectious lung diseases with basic lesions of alveolar unit inflammation and interstitial fibrosis. There are hundreds of kinds of ILD. The study of ILD subtypes in China found that the most common disease was idiopathic pulmonary fibrosis (IPF, 26.
View Article and Find Full Text PDFIn Vitro Analysis of Azithromycin's Effect on J774 Murine Macrophages Challenged with Aspergillus fumigatus: Azithromycin Improves Macrophage Response to Aspergillus fumigatus.
Immunol Lett
September 2025
Department of Clinical and Translational Science, College of Graduate Health Science, University of Tennessee Health Science Center, Memphis, Tennessee. Electronic address:
Background: Patients with chronic lung diseases often suffer from pulmonary aspergillosis, caused by Aspergillus fumigatus (AF). Alveolar macrophages play a key role in the initial immune response to AF. Azithromycin (AZM), commonly known for its immunomodulatory properties in reducing exacerbations and improving lung function, has mixed effects on the development of aspergillosis.
View Article and Find Full Text PDFAirway obstruction and gender affect arterial stiffness in children with cystic fibrosis.
Turk J Pediatr
September 2025
Department of Cardiorespiratory Physiotherapy and Rehabilitation, Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, Türkiye.
Background: Vascular changes are observed in children with cystic fibrosis (cwCF), and gender-specific differences may impact arterial stiffness. We aimed to compare arterial stiffness and clinical parameters based on gender in cwCF and to determine the factors affecting arterial stiffness in cwCF.
Methods: Fifty-eight cwCF were included.
Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis.
Pediatr Pulmonol
September 2025
Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Background: The approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF-related bone disease and body composition remain unclear.
Methods: This retrospective real-world study examined adults with CF who received ETI treatment.